-
2023-509296-16-00
4
2019-06-17
Moderate to severe hidradenitis suppurativa
-
2022-501970-20-01
5
2019-06-07
Cis-eligible Muscle-invasive bladder cancer.
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2022-501971-24-00
5
2019-05-20
Adjuvant treatment of HCC
-
2022-502187-20-00
5
2019-04-11
Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected eith
-
2023-503587-17-00
9
2019-03-20
Hematologic malignancies
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2022-502124-52-00
5
2018-12-18
Advanced epithelial ovarian cancer
-
2023-508955-37-00
5
2018-10-10
Moderate to severe atopic dermatitis
-
2023-507766-35-00
4
2018-01-09
Ulcerative Colitis or Crohn's Disease
-
2023-510200-42-00
5
2017-12-06
primary sclerosing cholangitis (PSC)
-
2023-507271-21-00
5
2017-04-11
Follicular Lymphoma
-
2023-507294-18-00
5
2016-09-16
Metastatic renal cell carcinoma
-
2023-509137-39-00
5
2015-11-06
Stage IB (T ≥ 4 cm), II and IIIA NSCLC
-
2023-504761-23-00
5
2014-11-19
Advanced or metastatic renal cell carcinoma
-
2023-506419-16-00
5
2013-01-08
Advanced Classical Hodgkin Lymphoma
-
2022-501353-37-00
5
Reversal of anticoagulation effect in patients on a FXa inhibitor (api
-
2023-503282-27-00
10
COVID-19
-
2023-503496-17-00
4
Diabetic Macular Edema (DME)
-
2023-510361-97-00
5
Newly Diagnosed RARA-positive Adult Patients with Higher-risk
Myelodys
-
2024-512477-27-00
4
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
-
2024-512986-15-00
4
Sjögren’s Disease
-
2025-522750-39-00
5
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)